<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206087</url>
  </required_header>
  <id_info>
    <org_study_id>PER977-01-002</org_study_id>
    <nct_id>NCT02206087</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin</brief_title>
  <official_title>Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of a Single Escalating Dose of PER977 Following Administration of Unfractionated Heparin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perosphere, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perosphere, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with
      dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of
      PER977 followed by a one-week washout and then will receive unfractionated heparin followed
      by a single dose of PER977. The study will provide some insight into the doses that may be
      required to reverse anticoagulation induced by heparin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of PER977 on reversal of heparin anticoagulation</measure>
    <time_frame>Single day dosing</time_frame>
    <description>To identify a dose of PER977 that reverses the effects of heparin as measured by whole blood clotting time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of PER977 administered following heparin</measure>
    <time_frame>Single day dosing</time_frame>
    <description>Number of participants with adverse events following the administration of PER977</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg PER977 or placebo administered following heparin sodium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg PER977 or placebo administered following heparin sodium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg PER977 or placebo administered following heparin sodium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg PER977 or placebo will be administered following heparin sodium injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg PER977 or placebo will be administered following heparin sodium injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PER977</intervention_name>
    <description>Reversal of heparin-induced anticoagulation</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Reversal of heparin-induced anticoagulation</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin Sodium</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults age 18 to 65 years, inclusive

          2. Laboratory values have no clinically significant abnormalities as judged by the
             Investigator.

          3. No clinically significant findings on 12-lead electrocardiogram

          4. Body mass index (BMI) 18 to ≤ 27 kg/m2, inclusive

          5. Male subjects agree to use appropriate contraception .

          6. Female subjects may be surgically sterile or post-menopausal or, if of child-bearing
             potential, must have a negative serum pregnancy test prior to enrollment, and must
             agree to use two forms of acceptable contraception for the duration of the study and
             for a minimum of one complete menstrual cycles or 28 days following discharge from the
             study.

          7. Subjects must understand and agree to comply with the requirements of the study and
             they must be willing to sign the informed consent form indicating voluntary consent to
             participate in the study prior to initiation of screening or study related activities.

        Exclusion Criteria:

          1. History or current evidence of clinically significant disease Current evidence of
             liver function tests or renal function tests (serum creatinine) greater than the upper
             limit of normal. The presence of Gilbert's Syndrome is acceptable. Current evidence of
             QTcF &gt;normal (450±10 msec for males or 470±10 msec for females).

          2. History of unexplained syncope

          3. Hypersensitivity to unfractionated heparin, thrombocytopenia with a positive in vitro
             test to anti-platelet antibody in the presence of unfractionated heparin,
             hypersensitivity to heparin or porcine products or any other contraindication to
             unfractionated heparin

          4. History of major bleeding, trauma, surgical procedure of any type, or vaginal delivery
             within six months prior to screening

          5. History of peptic ulcer, gastrointestinal bleeding or bleeding from hemorrhoids within
             six months prior to screening

          6. History of minor bleeding episodes such as epistaxis, or gingival bleeding within 1
             month prior to screening

          7. Personal or family history of clotting disorder or abnormality, excessive bleeding,
             thrombovascular disease or any hematologic disorder involving platelets or clotting
             abnormalities or any condition requiring treatment with transfusions, or personal
             history of heparin-induced thrombocytopenia

          8. Females with a history of dysfunctional uterine bleeding who have not undergone
             hysterectomy, including history of menorrhagia, metrorrhagia or polymenorrhea

          9. Pregnant or breast-feeding

         10. Males with a history of hormone therapy within 3 months prior to screening

         11. Administration of any blood product or anticoagulant within 3 months prior to study
             entry or any non-steroidal anti-inflammatory drug or cyclooxygenase inhibitor within 2
             weeks prior to dosing.

         12. Taking any type of medication for more than 14 consecutive days within the 4 weeks
             prior to study entry

         13. Positive serologic test for HIV, hepatitis C antibody, or hepatitis B surface antigen

         14. Donation of blood or blood products within 56 days prior to screening

         15. History of randomization in any prior study of PER977

         16. Randomization in any study with an investigational compound or device within 30 days
             prior to signing informed consent

         17. Active drug or alcohol dependence within the prior 12 months or any condition that, in
             the opinion of the Investigator, would interfere with adherence to study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Lomeli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <disposition_first_submitted>September 25, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 25, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 2, 2017</disposition_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PER977</keyword>
  <keyword>heparin</keyword>
  <keyword>anticoagulation reversal</keyword>
  <keyword>whole blood clotting time</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

